We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+72.19%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$416M
Cap. Flow
+$154M
Cap. Flow %
13.42%
Top 10 Hldgs %
42.31%
Holding
115
New
23
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.2M
2
APGE icon
Apogee Therapeutics
APGE
+$18.4M
3
ABVX
Abivax
ABVX
+$15.9M
4
SLNO
Soleno Therapeutics
SLNO
+$14.8M
5
CYTK icon
Cytokinetics
CYTK
+$14.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$32M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$12.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$8.84M
4
INZY
Inozyme Pharma
INZY
+$7M
5
VERA icon
Vera Therapeutics
VERA
+$5.59M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$66.7M 5.81%
625,000
+15,000
+2% +$1.57M
INSM icon
2
Insmed
INSM
$23.5B
$64.8M 5.65%
450,000
-25,000
-5% -$3.06M
SPY icon
3
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$56.3M 4.9%
+84,490
New +$54.2M
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.6B
$56.2M 4.9%
1,400,000
+300,000
+27% +$10.6M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.8B
$52.7M 4.59%
115,000
+35,000
+44% +$13.1M
APGE icon
6
Apogee Therapeutics
APGE
$10.1B
$46.6M 4.06%
1,173,426
+481,527
+70% +$18.4M
ACLX
7
DELISTED
Arcellx
ACLX
$41M 3.58%
500,000
+5,000
+1% +$360K
ALKS icon
8
Alkermes
ALKS
$8.79B
$37.5M 3.27%
1,250,000
+250,000
+25% +$7.05M
NUVL
9
DELISTED
Nuvalent
NUVL
$33.2M 2.9%
384,417
-30,583
-7% -$2.42M
ABVX
10
Abivax
ABVX
$11.9B
$30.6M 2.66%
360,000
+260,000
+260% +$15.9M
INSM icon
11
CALL
Insmed
INSM
$23.5B
$29.5M 2.57%
+205,000
New +$25.1M
MLYS icon
12
Mineralys Therapeutics
MLYS
$2.39B
$28.4M 2.48%
750,000
-150,000
-17% -$3.24M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$37.3B
$28.3M 2.46%
1,400,000
– –
MRUS
14
DELISTED
Merus
MRUS
$26.9M 2.34%
285,769
+215,769
+308% +$14.1M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$26.8M 2.34%
1,107,162
+207,000
+23% +$3.68M
LXEO icon
16
Lexeo Therapeutics
LXEO
$368M
$25.7M 2.24%
3,870,527
+281,172
+8% +$1.36M
TRVI icon
17
Trevi Therapeutics
TRVI
$2.71B
$25.6M 2.23%
2,800,000
+265,942
+10% +$1.99M
SYRE icon
18
Spyre Therapeutics
SYRE
$8.7B
$23.8M 2.07%
1,419,299
+812,621
+134% +$13.3M
RZLT icon
19
Rezolute
RZLT
$444M
$19.7M 1.72%
2,100,000
-100,000
-5% -$666K
CYTK icon
20
Cytokinetics
CYTK
$10.9B
$19.2M 1.68%
+350,000
New +$14.4M
ORKA
21
Oruka Therapeutics
ORKA
$5.59B
$18.4M 1.61%
959,180
+355,701
+59% +$5.27M
QURE icon
22
uniQure
QURE
$2.77B
$17.5M 1.53%
300,000
+165,000
+122% +$3M
WVE icon
23
Wave Life Sciences
WVE
$1.12B
$15.4M 1.34%
2,100,000
+99,692
+5% +$807K
PTGX icon
24
Protagonist Therapeutics
PTGX
$9.06B
$14.7M 1.28%
220,600
-219,400
-50% -$12.5M
EXEL icon
25
PUT
Exelixis
EXEL
$14.1B
$14.5M 1.26%
350,000
-100,000
-22% -$4.02M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Affinity Asset Advisors held 115 positions worth $1.15B, up 57% from $732M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $154M of net new capital in Q3 2025, opening 23 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $12.5M trimmed.

  • Affinity Asset Advisors's largest Q3 2025 buy was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q3 2025, an estimated $18.4M increase.
  • Affinity Asset Advisors's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $12.5M.
  • Affinity Asset Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $32M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.15B portfolio in Q3 2025.
  • Affinity Asset Advisors opened 23 new positions and closed 19 in Q3 2025.
  • Affinity Asset Advisors's portfolio value rose 57% quarter-over-quarter to $1.15B.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.